NewAmsterdam Pharma Q1 2025 10-Q Filed

Ticker: NAMSW · Form: 10-Q · Filed: May 8, 2025 · CIK: 1936258

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

NAMS Q1 2025 10-Q is in - check financials for earnout & stock option changes.

AI Summary

NewAmsterdam Pharma Co N.V. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including changes in fair value of earnouts and stock option activity. Key financial statement items like Additional Paid-In Capital and Retained Earnings are reported for the first quarter of 2025.

Why It Matters

This filing provides investors with an update on NewAmsterdam Pharma's financial health and operational performance for the first quarter of 2025.

Risk Assessment

Risk Level: medium — The filing contains detailed financial information, including fair value measurements and stock option activity, which can be complex for investors to fully analyze.

Key Numbers

Key Players & Entities

FAQ

What was the change in the fair value of the earnout during the first quarter of 2025?

The filing mentions 'ChangeInFairValueOfEarnout' in relation to the period ending March 31, 2025, indicating this is a reported item, but specific dollar amounts are not detailed in the provided header information.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

What is the Standard Industrial Classification code for NewAmsterdam Pharma Co N.V.?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What are the dates for the reporting period of this 10-Q?

The reporting period is from January 1, 2025, to March 31, 2025.

What former company name was NewAmsterdam Pharma Co N.V. previously known as?

The company was formerly known as NewAmsterdam Pharma Co B.V.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding NewAmsterdam Pharma Co N.V. (NAMSW).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing